CAR-T improves PFS for certain patients with gastric, gastroesophageal junction cancers
Click Here to Manage Email Alerts
Satricabtagene autoleucel improved PFS compared with physician’s choice of therapy for patients with Claudin18.2 expression-positive advanced gastric or gastroesophageal junction cancers, according to the agent’s manufacturer.
Satricabtagene autoleucel (CARsgen Therapeutics) — often called satri-cel — is an autologous chimeric antigen receptor T-cell product candidate that targets the protein Claudin18.2.
Researchers conducted an open-label phase 2 study to evaluate the efficacy and safety of satri-cel for patients with Claudin18.2 expression-positive, advanced gastric/gastroesophageal junction cancers who had failed at least two prior lines of therapy.
Investigators randomly assigned patients 2:1 to satri-cel or physician’s choice of treatment. Physician’s choice options included paclitaxel, docetaxel, irinotecan, apatinib or nivolumab (Opdivo, Bristol Myers Squibb).
The study met its primary endpoint, demonstrating a statistically significant improvement in PFS with satri-cel per independent review committee assessment.
“We are thrilled to see that satri-cel has achieved positive results in the pivotal phase 2 clinical trial in China,” Zonghai Li, MD, PhD, founder, chairman of the board, CEO and chief scientific officer of CARsgen Therapeutics, said in a press release. “We look forward to satri-cel becoming the world’s first CAR-T product for solid tumors, bringing hope to more patients as soon as possible. Additionally, we will continue to explore the potential of satri-cel in adjuvant therapy for gastric and pancreatic cancers, aiming to deliver even greater benefits to patients.”
Click Here to Manage Email Alerts